What is APUS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for APUS?

P/E (TTM) is n/a and 52-week range is $1.51 to $403.10 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s APUS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for APUS?

The company profile lists net income (TTM) near $-55M, EPS (TTM) near $-36.71 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Apimeds Pharmaceuticals US Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Matawan, New Jersey, US, 1.5M shares outstanding, ISIN US03771D1028 when available from company profile and filing metadata.

Apimeds Pharmaceuticals US Inc

$APUS

Health Care · Biotechnology

Run Scenarios

$5.02

-8.89%

Apimeds Pharmaceuticals US Inc

$APUS

Health Care · Biotechnology

Run Scenarios

$5.02

-8.89%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.

Employees

2

Website

www.apimedsus.com/

IPO

2025-05-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NYSE MKT LLC

ISIN

US03771D1028

Headquarters

Matawan, New Jersey, US

Shares outstanding

1.5M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

2.82%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.

Employees

2

Website

www.apimedsus.com/

IPO

2025-05-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)